SLC5A2 and aortic valve stenosis: In this analysis, SGLT2 inhibitor use was associated with a significantly lower risk of progression to severe AS (HR: 0.61; 95% CI: 0.39–0.94; p = 0.03), with an even greater risk reduction observed with longer treatment duration [118].